PSNL News and Press, Personalis Inc. From 11/06/19

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 7-10, including poster presentations on November 8 th and 9 th . ...

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its third quarter 2019 financial results after the market closes on Wednesday, November 13, 2019. In conjunction with the release, the Company will host a conference call and...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 in Boston, October 27-30, including a poster presentation on October 27...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress USA 2019 in San Diego on October 8 th at 2:50 PM PDT. The presentation , titled “Advancing Precision Oncology Biomarker...

Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at their lowest levels in months -- or ever. Shares of Adaptive Biotechnologies (NASDAQ: ADPT) f...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

Passive investing, or owning index funds and exchange-traded funds (ETFs) comprising a representation of the broader stock market, isn't inherently good or bad. It's certainly easier than conducting research and due diligence into individual companies. But some investors are beginning to think t...

Investors should be cautious when a business relies too heavily on a single customer. If the relationship changes or ends, then it's usually not very fun to be a shareholder. It can take years for the company and stock to recover -- if a recovery can be achieved at all. That's what makes the hi...

Personalis (NASDAQ: PSNL ) is up 5.8% postmarket after noting a new task order from the Dept. of Veterans Affairs. More news on: Personalis, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA’s Million Veteran Program (VA MVP). The new task order is effective on September 28, 2019. This is...